18009-07-9

Basic information

• Product Name: 6-BROMO-2-MERCAPTO-3-PHENYLQUINAZOLIN-4(3H)-ONE
• Synonyms: 4(3H)-Quinazolinone, 6-bromo-2-mercapto-3-phenyl- (8CI); NSC639726
• CAS NO: 18009-07-9
• Molecular Formula: C₁₄H₉BrN₂OS
• Molecular Weight: 333.2
• Mol File: 18009-07-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 469.6°C at 760 mmHg
• Flash Point: 237.8°C
• Appearance: /
• Density: 1.72g/cm³
• Vapor Pressure: 5.43E-09mmHg at 25°C
• Refractive Index: 1.78
• CAS DataBase Reference: 6-BROMO-2-MERCAPTO-3-PHENYLQUINAZOLIN-4(3H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-2-MERCAPTO-3-PHENYLQUINAZOLIN-4(3H)-ONE(18009-07-9)
• EPA Substance Registry System: 6-BROMO-2-MERCAPTO-3-PHENYLQUINAZOLIN-4(3H)-ONE(18009-07-9)

Safety Data

• Hazardous Substances Data: 18009-07-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H9BrN2OS/c15-9-6-7-12-11(8-9)13(18)17(14(19)16-12)10-4-2-1-3-5-10/h1-8H,(H,16,19)

Upstream product

• 103-72-0 phenyl isothiocyanate 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 4955-82-2 1-cyanothioformanilide 

Downstream Products

• 80416-48-4 1-[2-(6-Bromo-4-oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-acetyl]-3-(3-methoxy-phenyl)-urea 
• 80416-47-3 1-[2-(6-Bromo-4-oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-acetyl]-3-(2-methoxy-phenyl)-urea 
• 80416-44-0 1-[2-(6-Bromo-4-oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-acetyl]-3-phenyl-urea 
• 80416-49-5 1-[2-(6-Bromo-4-oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-acetyl]-3-(4-chloro-phenyl)-urea 
• 80416-45-1 1-[2-(6-Bromo-4-oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-acetyl]-3-o-tolyl-urea 
• 80416-46-2 1-[2-(6-Bromo-4-oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-acetyl]-3-m-tolyl-urea 
• 84772-19-0 6-bromo-2-hydrazino-3-phenyl-3H-quinazolin-4-one 
• 23965-11-9 6-bromo-3-phenylquinazoline-2,4(1H,3H)-dione 
• 116862-09-0 C₂₈H₁₆Br₂N₄O₂S 
• 174020-06-5 Acetic acid (2S,3R,4S,5S)-4,5-diacetoxy-2-(6-bromo-4-oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-tetrahydro-pyran-3-yl ester 
• 174020-06-5 Acetic acid (2S,3R,4S,5R)-4,5-diacetoxy-2-(6-bromo-4-oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-tetrahydro-pyran-3-yl ester 
• 18009-19-3 6-bromo-2-methylsulfanyl-3-phenyl-3H-quinazolin-4-one 
• 701245-01-4 C₂₁H₁₅BrN₂OS 
• 1402932-19-7 C₁₉H₁₇BrN₂OS 

Relevant articles and documents

Application of Deep Eutectic Solvents in the Synthesis of Substituted 2-Mercaptoquinazolin-4(3H)-Ones: A Comparison of Setected Green Chemistry Methods

In this study, deep eutectic solvents (DESs) were used as green and eco-friendly media for the synthesis of substituted 2-mercaptoquinazolin-4(3H)-ones from different anthranilic acids and aliphatic or aromatic isothiocyanates. A model reaction on anthranilic acid and phenyl isothiocyanate was porformed in 20 choline chloride-based DESs at 80 °C to find the best solvent. Based on the product yield, choline chloride-urea (1:2) DES was found to be the most effective, while DESs acted both as solvents and catalysts. Desired compounds were prepared with moderate to good yields using stirring, microwave-assisted, and ultrasound-assisted synthesis. Significantly, higher yields were obtained with mixing and ultrasonication (16-76%), while microwave-induced synthesis showed lower effectiveness (13-49%). The specific contribution of this research is the use of DESs in combination with the above-mentioned green techniques for the synthesis of a wide range of derivatives. The structures of the synthesized compounds were confirmed by1H and13C NMR spectroscopy.

Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents

Hepatitis C virus (HCV) assembles many host cellular proteins into unique membranous replication structures as a prerequisite for viral replication, and PI4KIIIα is an essential component of these replication organelles. RNA interference of PI4KIIIα results in a breakdown of this replication complex and cessation of HCV replication in Huh-7 cells. PI4KIIIα is a lipid kinase that interacts with the HCV nonstructural 5A protein (NS5A) and enriches the HCV replication complex with its product, phosphoinositol 4-phosphate (PI4P). Elevated levels of PI4P at the endoplasmic reticulum have been linked to HCV infection in the liver of HCV infected patients.1 We investigated if small molecule inhibitors of PI4KIIIα could inhibit HCV replication in vitro. The synthesis and structure-activity relationships associated with the biological inhibition of PI4KIIIα and HCV replication are described. These efforts led directly to identification of quinazolinone 28 that displays high selectivity for PI4KIIIα and potently inhibits HCV replication in vitro.

COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The invention relates to a series of dual inhibitors of enzymes PDE7 and PDE4, having formula (I) and to the use thereof in the production of pharmaceutical compositions for the treatment of inflammatory and/or autoimmune processes.